亞盛醫藥(06855.HK)發表治療耐藥非小細胞肺癌藥物之最新數據
亞盛醫藥(06855.HK)公布,在2021年世界肺癌大會(WCLC)上,已以小型口頭報告形式(Mini Oral Session)公布了原創雙靶點Bcl-2/Bcl-xL抑制劑pelcitoclax(APG-1252)聯合奧希替尼治療EGFR TKI(人表皮生長因子受體酪氨酸激(酉每)抑制劑)耐藥非小細胞肺癌(NSCLC)患者的Ib期臨床研究成果。
APG-1252為亞盛醫藥自主研發的新型Bcl-2/Bcl-xL雙靶點抑制劑,可通過同時選擇性抑制Bcl-2及Bcl-xL蛋白修復細胞凋亡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.